ABUS stock news

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 26) DURECT Corporation (NASDAQ: DRRX ) Stoke Therapeutics Inc (NASDAQ: STOK ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 26) Advaxis, Inc. (NASDAQ: ADXS ) Arbutus Biopharma Corp (NASDAQ: ABUS ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Avanos Medical Inc (NYSE: AVNS ) Cancer Genetics Inc (NASDAQ: CGIX ) Clearside Biomedical Inc (NASDAQ: CLSD ) Elanco Animal Health Inc (NYSE: ELAN )(Bank of America downgraded the shares to Neutral) Neurometrix Inc (NASDAQ: NURO ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tocagen Inc (NASDAQ: TOCA ) Unity Biotechnology Inc (NASDAQ: UBX ) Zafgen Inc (NASDAQ: ZFGN ) Stocks In Focus Nuvectra To Explore Strategic Options Nuvectra Corp (NASDAQ: NVTR ) announced its decision to explore strategic alternatives to … Read more
Arbutus (ABUS) delivered earnings and revenue surprises of -31.43% and -20.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 12) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) EXACT Sciences Corporation (NASDAQ: EXAS ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 12) Acorda Therapeutics Inc (NASDAQ: ACOR ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Melinta Therapeutics Inc (NASDAQ: MLNT ) Minerva Neurosciences Inc (NASDAQ: NERV ) Navidea Biopharmaceuticals Inc (NYSE: NAVB ) NextCure Inc (NASDAQ: NXTC ) Novavax, Inc. (NASDAQ: NVAX ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obseva SA (NASDAQ: OBSV ) RA Medical Systems Inc (NYSE: RMED ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Sensus Healthcare Inc (NASDAQ: SRTS ) Sierra Oncology Inc (NASDAQ: SRRA ) Unum Therapeutics Inc (NASDAQ: UMRX ) Zomedica Pharmaceuticals Corp (NYSE: ZOM ) Stock In Focus Savara's Pulmonary Disease Drug Does Not Meet Primary Endpoint In Late-stage Study Savara Inc (NASDAQ: SVRA ) said a Phase 3 study dubbed IMPALA that evaluated its … Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 5) Array Biopharma Inc (NASDAQ: ARRY ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) EXACT Sciences Corporation (NASDAQ: EXAS ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Misonix, Inc. (NASDAQ: MSON ) Repligen Corporation (NASDAQ: RGEN ) Uniqure NV (NASDAQ: QURE ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on June 5) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) ChemoCentryx Inc (NASDAQ: CCXI )(moved in sympathy with its rival, which has a competing drug) Collegium Pharmaceutical Inc (NASDAQ: COLL ) ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Harvard Bioscience, Inc. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) Chiasma Inc (NASDAQ: CHMA ) Soliton Inc (NASDAQ: SOLY )( reacted to the news of the initiation of cellulite trial) Eidos Therapeutics Inc (NASDAQ: EIDX ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 29) Abeona Therapeutics Inc (NASDAQ: ABEO ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) Allergan plc (NYSE: AGN ) AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) Aptinyx Inc (NASDAQ: APTX ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) CAN-FITE BIOPHA/S ADR (NYSE: CANF )(reacted to its first-quarter results and an update on clinical trial progress) Cidara Therapeutics Inc (NASDAQ: CDTX ) Diplomat Pharmacy Inc (NYSE: DPLO ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Emergent Biosolutions Inc (NYSE: EBS ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Hookipa Pharma Inc (NASDAQ: HOOK ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Melinta Therapeutics Inc (NASDAQ: MLNT ) Opko Health Inc. (NASDAQ: OPK ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Seres Therapeutics Inc (NASDAQ: MCRB ) Teva Pharmaceutical Industries Ltd (NYSE: TEVA )( downgraded by UBS to Neutral on its legal woes) Theravance Biopharma Inc (NASDAQ: TBPH ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Stock In Focus Unity … Read more
WARMINSTER, Pa., May 13, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ: ABUS ), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus' President and CEO, will present at the following conferences in May 2019: UBS Global Healthcare Conference – New York Monday, May … Full story available on Benzinga.com Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 8) Alcon AG (NYSE: ALC ) BioSig Technologies Inc (NASDAQ: BSGM ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 8) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aquestive Therapeutics Inc (NASDAQ: AQST )(reacted to first-quarter results) Arbutus Biopharma Corp (NASDAQ: ABUS ) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) Flexion Therapeutics Inc (NASDAQ: FLXN ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Opko Health Inc. (NASDAQ: OPK )(reacted to Q1 results) Osmotica Pharmaceuticals PLC (NASDAQ: OSMT ) Retrophin Inc (NASDAQ: RTRX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Sensus Healthcare Inc (NASDAQ: SRTS ) Stock In Focus Novartis to Buy Dry Eye Disease Drug From Takeda For $3.4B Novartis AG (NYSE: NVS ) announced an agreement with Takeda Pharmaceutical Co Ltd (NYSE: TAK ) to acquire the assets associated with Xildra, chemically lifitefgrast ophthalmic solution, 5 percent worldwide for a $3.4 billion payment upfront and potential milestone payments up to $1.9 billion. Read more
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2019 Results Earnings Conference Call May 06, 2019, 04:30 PM ET Company Participants Pam Murphy - IR Mark Murray Read more
Arbutus (ABUS) delivered earnings and revenue surprises of -51.61% and -40.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
WARMINSTER, Pa., April 29, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ: ABUS ), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its first quarter financial results, conference call and webcast for Monday, May 6, 2019. The schedule for the press release and conference call/webcast are as follows: • Q1 2019 Press Release: May 6, 2019 at 4:00 p.m. ET Read more
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more

Proudly made at

ROCKIT